Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

This randomized controlled trial examined effects of cholecalciferol supplementation in patients on hemodialysis.

Who Took Part

PubMed indexes the participants as young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

At baseline (autumn 2011) and 6 months, testing evaluated muscle strength, functional capacity, laboratory parameters, pulse wave velocity (PWV), and health-related quality of life (HRQOL) using the Kidney Disease Quality of Life-36 survey.

What Was Measured

Topics PubMed links to this paper include Analysis of Variance, Biomarkers, Biomechanical Phenomena, Cholecalciferol, Dietary Supplements, Health Status and Kidney Diseases.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.